
|Podcasts|November 13, 2009
Regulatory and Safety: Obesity Drugs
Advertisement
Diabetes & Obesity Series
Safety and Regulatory Aspects of Obesity Drugs
Subscribe to RSS feed of this series
Dr. David Orloff
Executive Director of Regulatory Affairs
Medpace
Dr. Orloff discusses the current and potential future regulatory issues for obesity and diabetes drugs, how FDA and industry is moving toward levels of safety for these drug classes.
Others in the Series
Diabetes Resources
- Articles, Multimedia
Diabetes Drugs in Development, 2009
Associations and Societies
Clinical Trials
Obesity Resources
Articles, Multimedia
Associations and Societies
Clinical Trials
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
2
ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle
3
HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research
4
ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology
5



